Guardant360® Tissue Receives MOHW LDTS approval in Taiwan
PR Newswire•10/11/2026•23:00 ET
0
Key Highlights
- ➤Guardant360 Tissue receives Taiwan MOHW LDTS approval
- ➤Approval creates a pathway to possible future reimbursement coverage
- ➤Copayment access will expand progressively across major Taiwanese hospitals
- ➤Guardant360 Tissue profiles 740+ DNA and 367 RNA genes
- ➤Guardant360 Tissue requires 92% less tissue surface area than industry standard
Expert Statements
Simranjit Singh, Chief Executive Officer, Guardant Health AMEA
“Taiwan's LDTS approval for Guardant360 Tissue expands patient access to comprehensive tumor profiling as part of an evolving precision oncology strategy. The approval complements the Guardant360 test, which received LDTS approval from MOHW in 2024. Guardant360 Tissue is the first approved test in Taiwan that includes both genomic and epigenomic insights. This gives clinicians a complete picture of cancer and more flexible testing options for improved clinical decision-making and patient care outcomes.”
Guardant360® Tissue Receives MOHW LDTS approval in Taiwan PR Newswire
Approval paves the way for possible reimbursement coverage in future
Get started
Create a free account to read the full story.